Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20487628 | 1.00 | PTPN1 (0.38) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL3661716 | 1.00 | PTPN1 (0.38) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL30890524 | 0.86 | PTPN1 (0.38) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL30890604 | 0.86 | PTPN1 (0.38) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL30890540 | 0.86 | PTPN1 (0.38) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL30890537 | 0.86 | PTPN1 (0.40) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL30890519 | 0.86 | PTPN1 (0.38) | PTPN1IMPDH2HDAC8NR1H2NR1H3 | |
| SCHEMBL19066055 | 0.86 | HSD17B10 (0.39) | HDAC8CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL20446514 | 0.86 | HSD17B10 (0.39) | HDAC8CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL15718593 | 0.86 | HSD17B10 (0.39) | HDAC8CHRM2CHRM1CHRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019022-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11807605-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2022-03-31 | — | — | US | disclosed |
| EP-3355890-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11066360-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2020-11-19 | — | — | US | disclosed |
| US-10562850-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180362458-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-20 | — | — | US | disclosed |
| EP-3355890-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066360-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PTPN1 2692/4885IMPDH2 3442/4885HDAC8 1767/4885 |
| US-20180362458-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PTPN1 2692/4885IMPDH2 3442/4885HDAC8 1767/4885 |
| US-10562850-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PTPN1 2692/4885IMPDH2 3442/4885HDAC8 1767/4885 |
| US-11807605-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | PTPN1 2692/4885IMPDH2 3442/4885HDAC8 1767/4885 |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PTPN1 2692/4885IMPDH2 3442/4885HDAC8 1767/4885 |
| US-20220098151-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | PTPN1 2692/4885IMPDH2 3442/4885HDAC8 1767/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | PTPN1 2663/4885IMPDH2 685/4885HDAC8 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.